Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial

AIMS: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Abhinav, Ambrosy, Andrew P., DeVore, Adam D., Margulies, Kenneth B., McNulty, Steven E., Mentz, Robert J., Hernandez, Adrian F., Michael Felker, Gary, Cooper, Lauren B., Lala, Anuradha, Vader, Justin, Groake, John D., Borlaug, Barry A., Velazquez, Eric J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300815/
https://www.ncbi.nlm.nih.gov/pubmed/30120812
http://dx.doi.org/10.1002/ehf2.12334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300815/
https://www.ncbi.nlm.nih.gov/pubmed/30120812
http://dx.doi.org/10.1002/ehf2.12334

Ejemplares similares